← Back to Clinical Trials
Recruiting NCT05768399

NCT05768399 The Role of Biomarkers in the Occurrence and Development of Asthma

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05768399
Status Recruiting
Phase
Sponsor Children's Hospital of Chongqing Medical University
Condition Asthma in Children
Study Type OBSERVATIONAL
Enrollment 2 participants
Start Date 2023-07-04
Primary Completion 2028-12-31

Eligibility & Interventions

Sex All sexes
Min Age 4 Years
Max Age 12 Years
Study Type OBSERVATIONAL
Interventions
The level of biomarkers in Peripheral blood

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 2 participants in total. It began in 2023-07-04 with a primary completion date of 2028-12-31.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

To study the expression level of biomarkers such as GITRL in peripheral blood of children with asthma and analyze their correlation with the severity of asthma. To study the predictive value of biomarkers level for the occurrence and development of asthma. And to provide supplementary detection means and predictive indicators for the diagnosis of asthma and the severity of asthma.

Eligibility Criteria

Inclusion Criteria: * In line with the diagnostic criteria in the Guidelines for the Diagnosis and Prevention of Bronchial Asthma in Children (2016 Edition) * Age: 4-12 years old for new diagnosis or recurrent episodes * Typical clinical manifestations and complete clinical data * Family members or guardians of children with informed research and signed consent * All healthy control subjects had no history of lung disease, allergic rhinitis or any other atopic disease Exclusion Criteria: * Suffering from other respiratory diseases (such as bronchiectasis, allergic rhinitis, respiratory failure, tuberculosis, obstructive airway disease) or other inflammatory diseases. * Abnormal development of congenital airway and lung tissue * History of immunosuppressant or glucocorticoid use in the first 4 weeks * Suffering from other endocrine system and immune system diseases * Incomplete clinical data or examinations.

Contact & Investigator

Central Contact

Ding Fengxia, PhD

✉ dingfengxia305@163.com

📞 86-15178712548

Frequently Asked Questions

Who can join the NCT05768399 clinical trial?

This trial is open to participants of all sexes, aged 4 Years or older, up to 12 Years, studying Asthma in Children. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05768399 currently recruiting?

Yes, NCT05768399 is actively recruiting participants. Contact the research team at dingfengxia305@163.com for enrollment information.

Where is the NCT05768399 trial being conducted?

This trial is being conducted at Chongqing, China.

Who is sponsoring the NCT05768399 clinical trial?

NCT05768399 is sponsored by Children's Hospital of Chongqing Medical University. The trial plans to enroll 2 participants.

Related Trials

Related Intelligence Guides

In-depth guides covering this condition's trials, eligibility, and what to expect.

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology